NYSE$LH

Laboratory Corp Of America Holdings · Q1 2022 earnings

Q1 2022 earnings · · Investor relations

Briefing

Labcorp's first quarter performance reflected a solid financial outcome despite Omicron's impact, with the company advancing its strategy through science, innovation, and technology.

Labcorp's Q1 2022 revenue reached $3.9 billion, a decrease from $4.2 billion year-over-year. Diluted EPS was $5.23, and adjusted EPS was $6.11. The company initiated a quarterly dividend and updated its full-year guidance, with adjusted EPS expected to be $18.25 to $21.00 and free cash flow projected at $1.7 billion to $1.9 billion.

  • Revenue for Q1 2022 was $3.9 billion, compared to $4.2 billion in the previous year.
  • Diluted EPS for Q1 2022 was $5.23, versus $7.82 last year.
  • Adjusted EPS for Q1 2022 was $6.11, compared to $8.79 last year.
  • Free cash flow for Q1 2022 was $239 million, a decrease from $1.1 billion in the prior year.

Headline financials

Total Revenue

$3.9B

Previous: $4.16B-6.3%
EPS (adj)

$6.11

Previous: $8.79-30.5%
TTM Net Orders

$7.2B

No prior period
TTM Book-to-Bill

1.23

Previous: 1.47-16.3%
Backlog

$15.2B

No prior period
Capital Expenditures

$117M

Previous: -$95.4M+222.9%
Free Cash Flow

$239M

Previous: $674M-64.6%
Net Income

$492M

Previous: $770M-36.1%
Operating Income

$688M

Previous: $1.06B-35.0%
Gross Profit

$1.23B

Previous: $1.6B-22.9%
Cash & Equivalents

$1.2B

Previous: $1.89B-36.5%
Total Assets

$20.7B

Previous: $20.4B+1.5%
Stock-Based Comp

$38.2M

Previous: $28.7M+33.1%

Revenue & EPS history

LabCorp · Revenue · Quarterly

$3.9B

Q1 2022-6.3%vs Q1 2021
Beat estimate in 12 of 16 quarters(75%)
ActualEstimate

Revenue by segment

LabCorp · $3.91B total across 2 segments · Q1 2022

  • Diagnostics Laboratories
    $2.45B-11.2%
  • Biopharma Laboratory Services
    $1.46B

Forward guidance

Labcorp is updating 2022 full year guidance to reflect its first quarter performance and full-year outlook. The following guidance assumes foreign exchange rates effective as of March 31, 2022, for the remainder of the year. Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases and dividends.

Tailwinds

  • Total Labcorp Enterprise Revenue between $(5.5%) and $(1.5%)
  • Base Business Revenue between 8.0% and 10.0%
  • COVID-19 Testing Revenue between (70.0%) and (60.0%)
  • Total Diagnostics Revenue between (15.5%) and (11.5%)
  • Total Drug Development Revenue between 6.0% and 8.5%

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2022

Historical avgQ1 2022

-0.3%

Avg return

Earnings day

-0.6%

Avg return

5 days after

-0.9%

Avg return

30 days after

48%

35 / 73 earnings

Positive

+9.5%

Q2 2024

Best reaction

-10.4%

Q3 2016

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-3.0%+0.0%+1.3%
Q4 2025-2.1%+0.0%-6.6%
Q3 2025-5.7%-7.9%-2.7%
Q2 2025-0.5%+1.2%+2.0%
Q1 2025+4.7%+7.9%+7.5%
Q4 2024-0.9%-1.9%+1.2%
Q3 2024+4.0%+3.7%+9.0%
Q2 2024+9.5%+4.8%+6.7%
Q1 2024-4.6%-3.2%-4.0%
Q4 2023-5.0%-5.5%-8.3%
Q3 2023+0.6%+1.0%+7.6%
Q2 2023-1.9%-2.4%-3.0%
Q1 2023-4.6%-2.5%-8.2%
Q4 2022+3.2%-0.4%-14.1%
Q3 2022-2.5%-3.2%+5.0%
Q2 2022+5.1%+1.2%-8.1%
Q1 2022-5.0%-3.1%+1.9%
Q4 2021-1.9%-6.0%-5.7%
Q3 2021+2.3%+2.0%+3.1%
Q2 2021+4.6%+6.0%+6.1%
Q1 2021+1.2%+4.1%+4.5%
Q4 2020+4.0%+3.1%+4.1%
Q3 2020+1.0%-1.1%-2.7%
Q2 2020-3.3%-4.2%-13.4%
Q1 2020-6.5%-10.4%-0.4%
Q4 2019+4.1%+1.8%-19.5%
Q3 2019-2.0%-2.3%+0.4%
Q2 2019-6.5%-4.2%-6.9%
Q1 2019+3.7%+6.1%+5.1%
Q4 2018+2.5%+3.8%+3.7%
Q3 2018-7.1%-6.2%-4.1%
Q2 2018-5.4%-6.4%-5.3%
Q1 2018+3.9%+2.8%+9.7%
Q4 2017+3.9%+3.0%+5.9%
Q3 2017+1.7%+2.2%+0.2%
Q2 2017+2.0%+1.3%-1.4%
Q1 2017-4.1%-3.1%-1.9%
Q4 2016+2.4%+2.4%+5.4%
Q3 2016-10.4%-9.4%-7.9%
Q2 2016+0.4%+1.2%-1.4%
Q1 2016+4.1%
Q4 2015+2.8%
Q3 2015+7.8%
Q2 2015+3.8%
Q1 2015-2.7%
Q4 2014+4.9%
Q3 2014+3.5%
Q2 2014-0.5%
Q1 2014-0.7%
Q4 2013+1.1%
Q3 2013-3.2%
Q2 2013+0.0%
Q1 2013+0.7%
Q4 2012-1.7%
Q3 2012-4.0%
Q2 2012-9.0%
Q1 2012-3.4%
Q4 2011+2.2%
Q3 2011-6.6%
Q2 2011-0.6%
Q1 2011+1.4%
Q4 2010-0.2%
Q4 2007-0.2%
Q3 2010+1.6%
Q2 2010+0.9%
Q1 2009+1.8%
Q1 2010+1.6%
Q4 2009-0.4%
Q2 2008-1.6%
Q3 2009-1.6%
Q3 2008-1.6%
Q4 2008-1.4%
Q2 2009-1.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro